VCA
ATRC icon

Verdence Capital Advisors’s AtriCure ATRC Stock Holding History

Verdence Capital Advisors’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,996
Closed -$219K – 661
2025
Q3 		$219K Buy
+5,996
New +$207K 0.01% 652

Other funds holding ATRC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Verdence Capital Advisors's ATRC Position: Q4 2025 in Review

Verdence Capital Advisors sold out of AtriCure (ATRC) in Q4 2025, closing a stake of 5,996 shares — an estimated $219K sold.

Verdence Capital Advisors first reported a position in ATRC in Q3 2025 and held it in 1 quarter. The position peaked at $219K in Q3 2025. 233 funds tracked by Wall St. Rank hold ATRC as of Q4 2025.

  • Verdence Capital Advisors reported no remaining AtriCure position as of Q4 2025 after selling out during the quarter.
  • Verdence Capital Advisors sold 5,996 AtriCure shares in Q4 2025, an estimated $219K.
  • Verdence Capital Advisors first reported a position in AtriCure in Q3 2025 and held it in 1 quarter.
  • Verdence Capital Advisors's AtriCure position peaked at $219K in Q3 2025.
  • 233 funds tracked by Wall St. Rank held AtriCure as of Q4 2025.

Based on Verdence Capital Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.